June Almenoff - Mar 28, 2025 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Director
Signature
/s/ Donald R. Reynolds, by Power of Attorney
Stock symbol
AVTX
Transactions as of
Mar 28, 2025
Transactions value $
$0
Form type
4
Date filed
4/1/2025, 04:22 PM
Previous filing
Dec 12, 2024
Next filing
Apr 2, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTX Common Stock Options Exercise +3.17K 3.17K Mar 28, 2025 Direct F1
holding AVTX Common Stock 1K Mar 28, 2025 By Meadowlark Management, LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Restricted Stock Units Options Exercise $0 -3.17K -33.34% $0.00 6.33K Mar 28, 2025 Common Stock 3.17K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.
F3 On August 13, 2024, the Reporting Person was granted 9,500 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.